RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+11.17%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.93B
AUM Growth
+$3.93B
(-2.9%)
Cap. Flow
-$151M
Cap. Flow
% of AUM
-3.83%
Top 10 Holdings %
Top 10 Hldgs %
32.87%
Holding
120
New
16
Increased
40
Reduced
11
Closed
6
Top Buys
| 1 |
Surgery Partners
SGRY
|
$29.4M |
| 2 |
Eli Lilly
LLY
|
$26.3M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$23.4M |
| 4 |
Viking Therapeutics
VKTX
|
$21.4M |
| 5 |
Oscar Health
OSCR
|
$20.4M |
Top Sells
Sector Composition
| 1 | Healthcare | 96.88% |
| 2 | Consumer Staples | 1.95% |
| 3 | Industrials | 0.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EDAP
76
EDAP TMS
EDAP
$84.5M
| $10.8M | 0.28% | 1,475,000 +88,575 | +6% | +$651K |
|
77
Mineralys Therapeutics
MLYS
$1.03B
| $10.2M | 0.26% | 792,615 -374,877 | -32% | -$4.84M |
|
78
Applied Therapeutics
APLT
$71M
| $10.2M | 0.26% | 1,497,918 +602,723 | +67% | +$4.1M |
|
79
Nuvalent
NUVL
$5.52B
| $9.41M | 0.24% | +125,302 | New | +$9.41M |
|
80
Acumen Pharmaceuticals
ABOS
$82.4M
| $9.32M | 0.24% | 2,300,059 | – | – |
|
81
Immatics
IMTX
$619M
| $8.92M | 0.23% | 848,751 -1,026,715 | -55% | -$10.8M |
|
82
Neumora Therapeutics
NMRA
$280M
| $8.88M | 0.23% | +646,118 | New | +$8.88M |
|
83
Enliven Therapeutics
ELVN
$1.2B
| $7.54M | 0.19% | +428,571 | New | +$7.54M |
|
84
CG Oncology
CGON
$2.04B
| $7.5M | 0.19% | +170,859 | New | +$7.5M |
|
85
Biohaven
BHVN
$1.63B
| $6.94M | 0.18% | +126,984 | New | +$6.94M |
|
86
Fulcrum Therapeutics
FULC
$351M
| $6.87M | 0.17% | 727,673 | – | – |
|
|
AUTL
87
Autolus Therapeutics
AUTL
$399M
| $6.59M | 0.17% | +1,032,988 | New | +$6.59M |
|
88
Pulmonx
LUNG
$69.7M
| $6.05M | 0.15% | 652,400 | – | – |
|
89
Aurinia Pharmaceuticals
AUPH
$1.58B
| $5.76M | 0.15% | 1,150,347 +737,777 | +179% | +$3.7M |
|
90
ESSA Pharma
EPIX
$11.4M
| $5.75M | 0.15% | 677,005 | – | – |
|
91
Pliant Therapeutics
PLRX
$101M
| $5.74M | 0.15% | 384,996 | – | – |
|
92
Beam Therapeutics
BEAM
$1.66B
| $4.87M | 0.12% | 147,510 +36,080 | +32% | +$1.19M |
|
|
VINC
93
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $4.51M | 0.11% | 891,719 | – | – |
|
94
Kyverna Therapeutics
KYTX
$160M
| $4.45M | 0.11% | +178,963 | New | +$4.45M |
|
95
Sagimet Biosciences
SGMT
$244M
| $4.18M | 0.11% | 770,671 +32,316 | +4% | +$175K |
|
96
Gossamer Bio
GOSS
$562M
| $3.86M | 0.1% | 3,266,960 | – | – |
|
|
ADAP
97
Adaptimmune Therapeutics
ADAP
$15.6M
| $3.83M | 0.1% | 2,425,468 | – | – |
|
98
Aclaris Therapeutics
ACRS
$209M
| $3.41M | 0.09% | 2,753,495 -245,000 | -8% | -$304K |
|
99
Compugen
CGEN
$132M
| $3.33M | 0.08% | 1,289,990 | – | – |
|
100
Amylyx Pharmaceuticals
AMLX
$836M
| $2.87M | 0.07% | 1,011,412 +476,400 | +89% | +$1.35M |
|